Empagliflozin helps obese mice use more fat, develop fat-burning cells, reduce inflammation, and improve insulin resistance by changing immune cells

Empagliflozin increased urinary glucose excretion and reduced weight gain in high-fat-diet-induced obese mice over 16 weeks.

• Empagliflozin enhanced energy expenditure and heat production in the studied mice.
• The treatment shifted energy metabolism towards fat utilization and elevated specific protein phosphorylation in skeletal muscle.
• Empagliflozin reduced insulin resistance and hepatic fat accumulation in high-fat-diet-induced obese mice.
• It altered macrophage behavior in white adipose tissue and liver, promoting an anti-inflammatory response.
• Plasma levels of a key growth factor associated with metabolism increased after empagliflozin treatment.

Simplified